Published in Science on August 22, 1997
Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc Natl Acad Sci U S A (2001) 7.15
The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev (2006) 6.80
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
Enzymatic pathways that regulate endocannabinoid signaling in the nervous system. Chem Rev (2008) 3.51
Endogenous cannabinoids mediate long-term synaptic depression in the nucleus accumbens. Proc Natl Acad Sci U S A (2002) 2.95
Molecular composition of the endocannabinoid system at glutamatergic synapses. J Neurosci (2006) 2.81
Pain modulation by release of the endogenous cannabinoid anandamide. Proc Natl Acad Sci U S A (1999) 2.31
Depolarization-induced suppression of excitation in murine autaptic hippocampal neurones. J Physiol (2005) 2.06
URB602 inhibits monoacylglycerol lipase and selectively blocks 2-arachidonoylglycerol degradation in intact brain slices. Chem Biol (2007) 2.05
Endocannabinoid signaling and synaptic function. Neuron (2012) 1.90
Supply and demand for endocannabinoids. Trends Neurosci (2011) 1.78
Identification of intracellular carriers for the endocannabinoid anandamide. Proc Natl Acad Sci U S A (2009) 1.77
The endocannabinoid system: a general view and latest additions. Br J Pharmacol (2004) 1.77
Evidence against the presence of an anandamide transporter. Proc Natl Acad Sci U S A (2003) 1.76
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
The endothelial component of cannabinoid-induced relaxation in rabbit mesenteric artery depends on gap junctional communication. J Physiol (1999) 1.69
Cellular accumulation of anandamide: consensus and controversy. Br J Pharmacol (2003) 1.66
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
The endocannabinoid system and pain. CNS Neurol Disord Drug Targets (2009) 1.59
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids. AAPS J (2005) 1.50
A catalytically silent FAAH-1 variant drives anandamide transport in neurons. Nat Neurosci (2011) 1.50
The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) (2009) 1.42
Regulation of CB1 cannabinoid receptor trafficking by the adaptor protein AP-3. FASEB J (2008) 1.40
The endogenous cannabinoid anandamide has effects on motivation and anxiety that are revealed by fatty acid amide hydrolase (FAAH) inhibition. Neuropharmacology (2007) 1.35
Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A (2005) 1.30
Direct inhibition of T-type calcium channels by the endogenous cannabinoid anandamide. EMBO J (2001) 1.29
Endocannabinoid mechanisms of pain modulation. AAPS J (2006) 1.28
TRPV1 in brain is involved in acetaminophen-induced antinociception. PLoS One (2010) 1.25
Effects of homologues and analogues of palmitoylethanolamide upon the inactivation of the endocannabinoid anandamide. Br J Pharmacol (2001) 1.25
Lipidomic analysis of endocannabinoid metabolism in biological samples. J Chromatogr B Analyt Technol Biomed Life Sci (2009) 1.23
Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration--comparison with CB(1) receptor blockade. Psychopharmacology (Berl) (2009) 1.19
Fatty acid-binding proteins transport N-acylethanolamines to nuclear receptors and are targets of endocannabinoid transport inhibitors. J Biol Chem (2011) 1.17
Further evidence for the existence of a specific process for the membrane transport of anandamide. Biochem J (2004) 1.16
Acute ethanol suppresses glutamatergic neurotransmission through endocannabinoids in hippocampal neurons. J Neurochem (2008) 1.11
More surprises lying ahead. The endocannabinoids keep us guessing. Neuropharmacology (2013) 1.10
Role of endocannabinoids in the pathogenesis of cirrhotic cardiomyopathy in bile duct-ligated rats. Br J Pharmacol (2005) 1.10
Endocannabinoid influence in drug reinforcement, dependence and addiction-related behaviors. Pharmacol Ther (2011) 1.08
The thrifty lipids: endocannabinoids and the neural control of energy conservation. Trends Neurosci (2012) 1.08
The endocannabinoid system as a target for the treatment of cannabis dependence. Neuropharmacology (2008) 1.07
Characterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamide. Br J Pharmacol (2001) 1.07
2012 Division of medicinal chemistry award address. Trekking the cannabinoid road: a personal perspective. J Med Chem (2014) 1.05
Anandamide-induced relaxation of sheep coronary arteries: the role of the vascular endothelium, arachidonic acid metabolites and potassium channels. Br J Pharmacol (2001) 1.05
Endocannabinoids and immune regulation. Pharmacol Res (2009) 1.04
Critical enzymes involved in endocannabinoid metabolism. Protein Pept Lett (2007) 1.04
The P2Y12 antagonists, 2-methylthioadenosine 5'-monophosphate triethylammonium salt and cangrelor (ARC69931MX), can inhibit human platelet aggregation through a Gi-independent increase in cAMP levels. J Biol Chem (2009) 1.03
Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. Curr Mol Pharmacol (2009) 1.02
Sapap3 deletion anomalously activates short-term endocannabinoid-mediated synaptic plasticity. J Neurosci (2011) 1.02
Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci (2009) 1.01
Increase of brain endocannabinoid anandamide levels by FAAH inhibition and alcohol abuse behaviours in the rat. Psychopharmacology (Berl) (2008) 1.01
Cannabinoids as therapeutic agents in cardiovascular disease: a tale of passions and illusions. Br J Pharmacol (2007) 1.01
AM404, an inhibitor of anandamide uptake, prevents pain behaviour and modulates cytokine and apoptotic pathways in a rat model of neuropathic pain. Br J Pharmacol (2006) 0.99
Cannabinoids, electrophysiology, and retrograde messengers: challenges for the next 5 years. AAPS J (2006) 0.98
Cannabidiol enhances consolidation of explicit fear extinction in humans. Psychopharmacology (Berl) (2013) 0.97
Divergent effects of anandamide transporter inhibitors with different target selectivity on social play behavior in adolescent rats. J Pharmacol Exp Ther (2008) 0.96
Characterization of an anandamide degradation system in prostate epithelial PC-3 cells: synthesis of new transporter inhibitors as tools for this study. Br J Pharmacol (2004) 0.96
The endocannabinoid signaling system: a potential target for next-generation therapeutics for alcoholism. Mini Rev Med Chem (2007) 0.95
N-Acylethanolamines in seeds. Quantification Of molecular species and their degradation upon imbibition Plant Physiol (1999) 0.94
Endocannabinoid-mediated synaptic plasticity and addiction-related behavior. Neuropharmacology (2011) 0.94
Inhibition of fatty acid amide hydrolase and monoacylglycerol lipase by the anandamide uptake inhibitor VDM11: evidence that VDM11 acts as an FAAH substrate. Br J Pharmacol (2005) 0.94
Endocannabinoids and the heart. J Cardiovasc Pharmacol (2009) 0.94
"Redundancy" of endocannabinoid inactivation: new challenges and opportunities for pain control. ACS Chem Neurosci (2012) 0.93
Glucocorticoids shift arachidonic acid metabolism toward endocannabinoid synthesis: a non-genomic anti-inflammatory switch. Eur J Pharmacol (2008) 0.93
Pharmacological characterization of endocannabinoid transport and fatty acid amide hydrolase inhibitors. Cell Mol Neurobiol (2006) 0.93
Comparison of the pharmacological properties of EDHF-mediated vasorelaxation in guinea-pig cerebral and mesenteric resistance vessels. Br J Pharmacol (2000) 0.92
Chronic ethanol treatment potentiates ethanol-induced increases in interstitial nucleus accumbens endocannabinoid levels in rats. J Neurochem (2009) 0.92
Role of cannabinoids and endocannabinoids in cerebral ischemia. Curr Pharm Des (2008) 0.92
Cannabinoid-related agents in the treatment of anxiety disorders: current knowledge and future perspectives. Recent Pat CNS Drug Discov (2012) 0.91
Studies of anandamide accumulation inhibitors in cerebellar granule neurons: comparison to inhibition of fatty acid amide hydrolase. J Mol Neurosci (2007) 0.91
β-Lactones Inhibit N-acylethanolamine Acid Amidase by S-Acylation of the Catalytic N-Terminal Cysteine. ACS Med Chem Lett (2012) 0.91
Enhancement of endocannabinoid signaling and the pharmacotherapy of depression. Pharmacol Res (2007) 0.91
Neuropharmacology of the endocannabinoid signaling system-molecular mechanisms, biological actions and synaptic plasticity. Curr Neuropharmacol (2007) 0.90
Supraspinal modulation of pain by cannabinoids: the role of GABA and glutamate. Br J Pharmacol (2007) 0.90
Mode of action of cannabinoids on nociceptive nerve endings. Exp Brain Res (2009) 0.90
Regulation of gonadotropin-releasing hormone secretion by cannabinoids. Endocrinology (2005) 0.90
Effects of opioids, cannabinoids, and vanilloids on body temperature. Front Biosci (Schol Ed) (2011) 0.90
Lead discovery, chemistry optimization, and biological evaluation studies of novel biamide derivatives as CB2 receptor inverse agonists and osteoclast inhibitors. J Med Chem (2012) 0.89
Diuretic effects of cannabinoids. J Pharmacol Exp Ther (2012) 0.89
The group IV afferent neuron expresses multiple receptor alterations in cardiomyopathyic rats: evidence at the cannabinoid CB1 receptor. J Physiol (2007) 0.88
Differential endocannabinoid regulation of baroreflex-evoked sympathoinhibition in normotensive versus hypertensive rats. Auton Neurosci (2009) 0.88
The 'specific' tyrosine kinase inhibitor genistein inhibits the enzymic hydrolysis of anandamide: implications for anandamide uptake. Br J Pharmacol (2007) 0.88
Acetaminophen differentially enhances social behavior and cortical cannabinoid levels in inbred mice. Prog Neuropsychopharmacol Biol Psychiatry (2012) 0.87
Modulation of the serotonin system by endocannabinoid signaling. Neuropharmacology (2011) 0.87
Development of novel tail-modified anandamide analogs. Bioorg Med Chem Lett (2008) 0.87
The anandamide transport inhibitor AM404 reduces the rewarding effects of nicotine and nicotine-induced dopamine elevations in the nucleus accumbens shell in rats. Br J Pharmacol (2012) 0.87
A possible role for the endocannabinoid system in the neurobiology of depression. Clin Pract Epidemiol Ment Health (2007) 0.87
[Cannabinoids--signal transduction and mode of action]. Schmerz (2005) 0.87
Characterization of the effects of reuptake and hydrolysis inhibition on interstitial endocannabinoid levels in the brain: an in vivo microdialysis study. ACS Chem Neurosci (2012) 0.86
Effects of endocannabinoid neurotransmission modulators on brain stimulation reward. Psychopharmacology (Berl) (2006) 0.86
Anandamide metabolism by fatty acid amide hydrolase in intact C6 glioma cells. Increased sensitivity to inhibition by ibuprofen and flurbiprofen upon reduction of extra- but not intracellular pH. Naunyn Schmiedebergs Arch Pharmacol (2003) 0.86
The cannabinomimetic arachidonyl-2-chloroethylamide (ACEA) acts on capsaicin-sensitive TRPV1 receptors but not cannabinoid receptors in rat joints. Br J Pharmacol (2004) 0.86
Endocannabinoids mediate muscarine-induced synaptic depression at the vertebrate neuromuscular junction. Eur J Neurosci (2007) 0.85
Fatty acid amide hydrolase-dependent generation of antinociceptive drug metabolites acting on TRPV1 in the brain. PLoS One (2013) 0.85
The endocannabinoid transport inhibitor AM404 differentially modulates recognition memory in rats depending on environmental aversiveness. Front Behav Neurosci (2012) 0.85
Is there a temperature-dependent uptake of anandamide into cells? Br J Pharmacol (2006) 0.85
Augmentation of endogenous cannabinoid tone modulates lipopolysaccharide-induced alterations in circulating cytokine levels in rats. Immunology (2008) 0.85
Mechanisms for recycling and biosynthesis of endogenous cannabinoids anandamide and 2-arachidonylglycerol. J Neurochem (2008) 0.84
Evaluation of interactions between cannabinoid compounds and diazepam in electroshock-induced seizure model in mice. J Neural Transm (Vienna) (2008) 0.84
A role for the anandamide membrane transporter in TRPV1-mediated neurosecretion from trigeminal sensory neurons. Neuropharmacology (2005) 0.84
Endocannabinoid system: emerging role from neurodevelopment to neurodegeneration. Mini Rev Med Chem (2009) 0.84
A high-density rice genetic linkage map with 2275 markers using a single F2 population. Genetics (1998) 6.82
Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature (1994) 5.70
Lac repressor binding to non-operator DNA: detailed studies and a comparison of eequilibrium and rate competition methods. J Mol Biol (1972) 5.62
Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc Natl Acad Sci U S A (2002) 5.33
A 300 kilobase interval genetic map of rice including 883 expressed sequences. Nat Genet (1994) 5.08
A second endogenous cannabinoid that modulates long-term potentiation. Nature (1997) 4.79
Control of pain initiation by endogenous cannabinoids. Nature (1998) 4.73
Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci (1999) 3.45
The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci (2000) 3.41
Antidepressant-like activity and modulation of brain monoaminergic transmission by blockade of anandamide hydrolysis. Proc Natl Acad Sci U S A (2005) 2.96
An anorexic lipid mediator regulated by feeding. Nature (2001) 2.94
The mechanism of sodium fluoride and cycloheximide inhibition of hemoglobin biosynthesis in the cell-free reticulocyte system. J Mol Biol (1966) 2.91
Structure-activity relationships of pyrazole derivatives as cannabinoid receptor antagonists. J Med Chem (1999) 2.73
Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br J Pharmacol (1999) 2.56
Evidence supporting the existence of an activity-dependent astrocyte-neuron lactate shuttle. Dev Neurosci (1998) 2.54
CB2 cannabinoid receptor-mediated peripheral antinociception. Pain (2001) 2.38
Lac operator analogues: bromodeoxyuridine substitution in the lac operator affects the rate of dissociation of the lac repressor. Proc Natl Acad Sci U S A (1972) 2.36
Lipoxygenase metabolites of arachidonic acid as second messengers for presynaptic inhibition of Aplysia sensory cells. Nature (1987) 2.32
HER-2/neu blocks tumor necrosis factor-induced apoptosis via the Akt/NF-kappaB pathway. J Biol Chem (2000) 2.29
Segregation of two endocannabinoid-hydrolyzing enzymes into pre- and postsynaptic compartments in the rat hippocampus, cerebellum and amygdala. Eur J Neurosci (2004) 2.25
Photochemical attachment of lac repressor to bromodeoxyuridine-substituted lac operator by ultraviolet radiation. Proc Natl Acad Sci U S A (1974) 2.20
Occurrence and biosynthesis of endogenous cannabinoid precursor, N-arachidonoyl phosphatidylethanolamine, in rat brain. J Neurosci (1997) 1.99
Anandamide amidohydrolase activity in rat brain microsomes. Identification and partial characterization. J Biol Chem (1995) 1.98
Mapping of quantitative trait loci controlling low-temperature germinability in rice (Oryza sativa L.). Theor Appl Genet (2003) 1.92
Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes. Nature (1995) 1.83
(R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J Med Chem (1994) 1.80
Endocannabinoids acting at vascular CB1 receptors mediate the vasodilated state in advanced liver cirrhosis. Nat Med (2001) 1.80
123I-labeled AM251: a radioiodinated ligand which binds in vivo to mouse brain cannabinoid CB1 receptors. Eur J Pharmacol (1996) 1.78
Brain cannabinoids in chocolate. Nature (1996) 1.78
Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry (2012) 1.77
Functional CB1 cannabinoid receptors in human vascular endothelial cells. Biochem J (2000) 1.75
The endocannabinoid system in brain reward processes. Br J Pharmacol (2008) 1.71
Hepatitis B virus markers in Chinese twins. Anticancer Res (1989) 1.68
Anandamide transport is independent of fatty-acid amide hydrolase activity and is blocked by the hydrolysis-resistant inhibitor AM1172. Proc Natl Acad Sci U S A (2004) 1.66
Intraosseous lipoma of the left frontoethmoidal sinuses and nasal cavity. AJNR Am J Neuroradiol (2007) 1.64
Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry (2012) 1.63
Mechanism involved in initiation and propagation of receptor-induced intercellular calcium signaling in cultured rat astrocytes. J Neurosci (1997) 1.62
Lac repressor binding to operator analogues: comparison of poly(d(A-T)), poly(d(A-BrU)), and poly(d(A-U)). Biochem Biophys Res Commun (1971) 1.62
Biosynthesis of an endogenous cannabinoid precursor in neurons and its control by calcium and cAMP. J Neurosci (1996) 1.62
Quantification of bioactive acylethanolamides in rat plasma by electrospray mass spectrometry. Anal Biochem (2000) 1.61
CB2 receptor-mediated migration of immune cells: it can go either way. Br J Pharmacol (2007) 1.55
All-metallic three-dimensional photonic crystals with a large infrared bandgap. Nature (2002) 1.54
Structural determinants for recognition and translocation by the anandamide transporter. Proc Natl Acad Sci U S A (1999) 1.51
Growth/cell cycle regulation of Sp1 phosphorylation. J Biol Chem (1999) 1.49
Angiotensin receptors. Am J Physiol (1970) 1.49
Brain-derived neurotrophic factor rapidly enhances phosphorylation of the postsynaptic N-methyl-D-aspartate receptor subunit 1. Proc Natl Acad Sci U S A (1997) 1.47
AM630, a competitive cannabinoid receptor antagonist. Life Sci (1995) 1.46
Receptor-dependent formation of endogenous cannabinoids in cortical neurons. Eur J Pharmacol (2001) 1.45
Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. Eur J Pharmacol (2001) 1.45
The cannabinoid CB1 antagonists SR 141716A and AM 251 suppress food intake and food-reinforced behavior in a variety of tasks in rats. Behav Pharmacol (2003) 1.44
Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J Med Chem (1999) 1.44
Endocannabinoids control spasticity in a multiple sclerosis model. FASEB J (2000) 1.44
Regulation of food intake by oleoylethanolamide. Cell Mol Life Sci (2005) 1.43
Binding of the non-classical cannabinoid CP 55,940, and the diarylpyrazole AM251 to rodent brain cannabinoid receptors. Life Sci (1997) 1.42
Selective activation of cannabinoid CB(2) receptors suppresses spinal fos protein expression and pain behavior in a rat model of inflammation. Neuroscience (2003) 1.42
Structure and orientation of the pore-forming peptide, melittin, in lipid bilayers. J Mol Biol (1994) 1.39
Elevated endogenous cannabinoids in schizophrenia. Neuroreport (1999) 1.38
Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection. J Clin Oncol (1990) 1.38
Bidirectional control of airway responsiveness by endogenous cannabinoids. Nature (2000) 1.36
(R)-methanandamide and Delta 9-THC as discriminative stimuli in rats: tests with the cannabinoid antagonist SR-141716 and the endogenous ligand anandamide. Psychopharmacology (Berl) (2001) 1.36
Carrier-mediated transport and enzymatic hydrolysis of the endogenous cannabinoid 2-arachidonylglycerol. Neuroreport (2000) 1.36
Mechanisms of endocannabinoid inactivation: biochemistry and pharmacology. J Pharmacol Exp Ther (2001) 1.33
Activation of cannabinoid CB2 receptors suppresses C-fiber responses and windup in spinal wide dynamic range neurons in the absence and presence of inflammation. J Neurophysiol (2004) 1.33
Carcinoma of major salivary glands. Recent trends. Arch Otolaryngol Head Neck Surg (1989) 1.32
A novel peripherally restricted cannabinoid receptor antagonist, AM6545, reduces food intake and body weight, but does not cause malaise, in rodents. Br J Pharmacol (2010) 1.32
Elevated brain cannabinoid CB1 receptor availability in post-traumatic stress disorder: a positron emission tomography study. Mol Psychiatry (2013) 1.32
Activation of peripheral cannabinoid CB1 and CB2 receptors suppresses the maintenance of inflammatory nociception: a comparative analysis. Br J Pharmacol (2006) 1.32
Synthesis and antihistaminic activity of some thiazolidin-4-ones. J Med Chem (1992) 1.31
Reversal of dopamine D(2) receptor responses by an anandamide transport inhibitor. J Neurosci (2000) 1.31
Arachidonate 5-lipoxygenase and its activating protein: prominent hippocampal expression and role in somatostatin signaling. J Neurochem (1996) 1.28
Large receptor reserve for cannabinoid actions in the central nervous system. J Pharmacol Exp Ther (1999) 1.26
NO-naproxen vs. naproxen: ulcerogenic, analgesic and anti-inflammatory effects. Aliment Pharmacol Ther (1997) 1.26
Exercise activates the endocannabinoid system. Neuroreport (2003) 1.25
AM630 antagonism of cannabinoid-stimulated [35S]GTP gamma S binding in the mouse brain. Eur J Pharmacol (1997) 1.25
Herbal treatment for renal diseases. Ann Acad Med Singapore (2005) 1.25
The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology (2001) 1.24
Lac repressor binding to DNA not containing the lac operator and to synthetic poly dAT. Nature (1970) 1.23
MR evaluation of tuberculous spondylitis. Acta Radiol (1993) 1.22
Structural requirements for cannabinoid receptor probes. Handb Exp Pharmacol (2005) 1.22
Elevated circulating levels of anandamide after administration of the transport inhibitor, AM404. Eur J Pharmacol (2000) 1.21
Activation of cannabinoid CB1 and CB2 receptors suppresses neuropathic nociception evoked by the chemotherapeutic agent vincristine in rats. Br J Pharmacol (2007) 1.21
Phylogenetic analysis of classical swine fever virus in Taiwan. Arch Virol (2005) 1.17
Anandamide transport inhibition by the vanilloid agonist olvanil. Eur J Pharmacol (1999) 1.17
Effect of phenylmethylsulphonyl fluoride on the potency of anandamide as an inhibitor of electrically evoked contractions in two isolated tissue preparations. Eur J Pharmacol (1995) 1.17
Imaging the brain marijuana receptor: development of a radioligand that binds to cannabinoid CB1 receptors in vivo. J Neurochem (1998) 1.16
Partial characterization of the enzymatic properties of the aminoacyl transfer ribonucleic acid binding enzyme. J Biol Chem (1969) 1.16
Characterization of the L lambda phase in trehalose-stabilized dry membranes by solid-state NMR and X-ray diffraction. Biochemistry (1989) 1.15
NO-naproxen modulates inflammation, nociception and downregulates T cell response in rat Freund's adjuvant arthritis. Br J Pharmacol (2000) 1.14
Minimal requirements for IgE-mediated regulation of surface Fc epsilon RI. J Immunol (2001) 1.14
Fatty acid sulfonyl fluorides inhibit anandamide metabolism and bind to the cannabinoid receptor. Biochem Biophys Res Commun (1997) 1.14
Role of three-dimensional power Doppler in the antenatal diagnosis of placenta accreta: comparison with gray-scale and color Doppler techniques. Ultrasound Obstet Gynecol (2009) 1.14
The cannabinoid CB1 antagonist AM 251 produces food avoidance and behaviors associated with nausea but does not impair feeding efficiency in rats. Psychopharmacology (Berl) (2005) 1.13
Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J Med Chem (1996) 1.12
Deuterium NMR investigation of ether- and ester-linked phosphatidylcholine bilayers. Biochemistry (1985) 1.12
Cyclooxygenase-independent chemoprevention with an aspirin derivative in a rat model of colonic adenocarcinoma. Life Sci (1998) 1.11
Modulation of neuropathic and inflammatory pain by the endocannabinoid transport inhibitor AM404 [N-(4-hydroxyphenyl)-eicosa-5,8,11,14-tetraenamide]. J Pharmacol Exp Ther (2006) 1.11
Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J Med Chem (1998) 1.11